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Background & aims: Chronic Fatigue Syndrome (CFS) is a complex condition, characterized by severe
disabling fatigue with no known cause, no established diagnostic tests, and no universally effective
treatment. Several studies have proposed symptomatic treatment with coenzyme Q10 (CoQ10) and
nicotinamide adenine dinucleotide (NADH) supplementation. The primary endpoint was to assess the
effect of CoQ10 plus NADH supplementation on age-predicted maximum heart rate (max HR) during a
cycle ergometer test. Secondary measures included fatigue, pain and sleep.
Methods: A proof-of-concept, 8-week, randomized, controlled, double-blind trial was conducted in 80
CFS patients assigned to receive either CoQ10 plus NADH supplementation or matching placebo twice
daily. Maximum HR was evaluated at baseline and at end of the run-in period using an exercise test.
Fatigue, pain and sleep were evaluated at baseline, and then reassessed at 4- and 8-weeks through self-
reported questionnaires.
Results: The CoQ10 plus NADH group showed a signiﬁcant reduction in max HR during a cycle ergometer
test at week 8 versus baseline (P ¼ 0.022). Perception of fatigue also showed a decrease through all
follow-up visits in active group versus placebo (P ¼ 0.03). However, pain and sleep did not improve in the
active group. Coenzyme Q10 plus NADH was generally safe and well tolerated.
Conclusions: Our results suggest that CoQ10 plus NADH supplementation for 8 weeks is safe and
potentially effective in reducing max HR during a cycle ergometer test and also on fatigue in CFS. Further
additional larger controlled trials are needed to conﬁrm these ﬁndings.
Clinical trial registrationThis trial was registered at clinicaltrials.gov as NCT02063126.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic Fatigue Syndrome (CFS) is a complex and extremely
debilitating condition with no known cause, no established5 e Floor 1), Vall d'Hebron
l d'Hebron 119-129 E-08035,
34 93 2746708.
rrero).
y to this study.
Ltd. This is an open access article udiagnostic tests, and no universally effective therapy. Its symptoms
are characterized by extreme disabling fatigue that does not
improve with rest, persists for more than six months and cannot be
explained by any underlyingmedical condition. It is associatedwith
other symptoms including muscle pain, sleep dysfunction and
cognitive problems. Chronic fatigue may worsen with physical and
mental activity, and exercise intolerance is a frequent complaint in
most CFS patients [1]. Currently there is no known universally
effective treatment for CFS, and the available therapy options focus
on symptom relief [2,3]. Coenzyme Q10 (CoQ10) and reduced nico-
tinamide adenine dinucleotide (NADH) are common antioxidantnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations
ATP adenosine triphosphate
CFS chronic fatigue syndrome
CoQ10 coenzyme Q10
DBP diastolic blood pressure
max HR maximum heart rate
NADH reduced nicotinamide adenine dinucleotide
PBMC peripheral blood mononuclear cells
SBP systolic blood pressure
VO2 pulmonary oxygen uptake
VCO2 pulmonary carbon dioxide uptake
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used for several decades as dietary supplements for general health
maintenance. The beneﬁts of their administration have been most
extensively evaluated in cardiovascular and neurodegenerative
conditions [4,6e8]. However, several studies have shown that there
is a mitochondrial failure which reduces the rate of adenosine-5-
triphosphate (ATP) synthesis, the central agent of energy produc-
tion inmost CFS patients [9e11]. Because CoQ10 and NADH increase
cellular ATP production via mitochondrial oxidative phosphoryla-
tion, their supplementation could help improve fatigue and other
symptoms in CFS [12,13]. A previous study by our group showed
that oral NADH (20 mg/day) administration for eight weeks was
associated with reductions in anxiety and maximum HR after a
stress test in 77 Spanish CFS patients [14]. Another placebo-
controlled cross-over study in 26 CFS patients found that those
who received NADH (10 mg/day) supplementation for 12 weeks
obtained more effective symptom relief than those assigned to the
placebo (31% vs. 8% respectively) [15]. A study comparing oral
NADH supplementation with conventional therapy for 24 months
in 31 CFS patients showed a higher effectiveness of NADH (in terms
of the reduction in the mean symptom score) over nutritional
supplements and psychotherapy [16]. Previous studies have shown
that oral NADH administration has a good safety proﬁle, with no
observed adverse effects or toxicity [14e17]. For its part, CoQ10
supplementation has been evaluated in many illnesses, such as ﬁ-
bromyalgia, with conﬂicting ﬁndings [18]. For instance, an effect on
dyspnea and exercise tolerance has been described in patients with
congestive heart failure and/or cardiomyopathy and an increased
time to exhaustion following two weeks of CoQ10 in trained and
untrained individuals [4,19,20]. However, the data regarding the
effects of CoQ10 and NADH supplementation on exercise perfor-
mance and cardinal symptoms in CFS remain limited and incon-
sistent. Additionally, no speciﬁc assessment of cardiovascular
functioning with CoQ10 plus NADH supplementation during a stress
test in CFS has been performed to date. Our aim was to conduct an
8-week, randomized, double-blind, controlled trial to evaluate the
clinical response after CoQ10 plus NADH supplementation on car-
diovascular function (max HR changes) during an incremental cycle
ergometer test, and to assess perceptions of fatigue, pain and sleep
disturbances in a sample of CFS patients.
2. Subjects and methods
2.1. Study participants and recruitment
An 8-week randomized, placebo-controlled, double-blind pilot
study was conducted at a single tertiary referral center (CFS Clinical
Unit, Vall d'Hebron University Hospital, Barcelona, Spain) from
January to December 2013. A total of 113 potentially eligiblepatients were enrolled. At enrollment, 33 patients (29.2%) who
failed to satisfy all inclusion criteria or presented one or more
exclusion criteria were excluded from the study. The remaining 80
fully eligible patients (70.8%, mean age, 49.2 ± 7.8 years) were
included in the study. The reasons for rejection of potentially
eligible patients are shown in Fig. 1. Inclusion criteria were female
sex, age between 18 and 65 years with a conﬁrmed diagnosis of CFS
according to 1994 CDC case criteria. All participants had a resting
radial pulse rate between 50 and 100 bpm, systolic blood pressure
between 100 and 140 mmHg and diastolic blood pressure between
50 and 90 mm Hg. Exclusion criteria were contraindication of an
ergometer exercise test, participation in other trials in the 30 days
prior to inclusion, intake of any drug or banned substances (statins,
dietary supplements, anti-hypertension or beta-blocker drugs),
pregnancy or breast-feeding, secondary hypertension, hep-
atobiliary tract disease that might alter CoQ10 bioavailability, car-
diovascular or pulmonary disorder (unstable angina pectoris, heart
failure, life-threatening arrhythmia) that might interfere with
maximal exercise testing, and inability to communicate and comply
with all study requirements.
2.2. Intervention
Eighty participants were randomized in a double-blind fashion
in a 1:1 ratio and assigned to receive either CoQ10 plus NADH
(n ¼ 40) or matching placebo (n ¼ 40) in enteric-coated tablets
twice daily for 8-weeks, in addition to standard therapy. To allocate
participants, we applied a computer-generated list of random-
numbers using Stata 9.0 (StataCorp, College Station, TX, USA) sta-
tistical software. Participants were instructed to avoid taking any
additional supplements containing CoQ10, NADH, phosphati-
dylserine and vitamin C during the study. Adherence to study
medications was assessed by serial measures of CoQ10 and NADH
levels in peripheral blood mononuclear cells (PBMC) at baseline
and following eight weeks of therapy. Patients randomized to the
CoQ10 plus NADH group received four enteric-coated tablets daily
consisting of active ingredients (50 mg of CoQ10 and 5mg of NADH)
and excipients (20 mg of phosphatidylserine and 40 mg of vitamin
C). Patients randomized to placebo received supplementation
comprising four enteric-coated tablets daily without active in-
gredients and containing only excipients. Both active and placebo
tablets, were identical in size, color, opacity, shape, presentation
and packaging. All tablets weremanufactured and donated by Vitae
Natural Nutrition Corporation, S.L. (Sant Cugat de Valles, Barcelona,
Spain). Telephone calls were made at two, four and eight weeks of
the intervention to encourage compliance and to record the
average number of tablets not taken during the previous month.
Participants were supplied with excess tablets. The number of
tablets returned and PBMC CoQ10 and NADH levels at week 8 were
used as a measure of compliance. Evidence of adverse effects of
CoQ10 and NADH could include insomnia, elevated liver enzymes,
rash, nausea, vomiting, epigastric pain, diarrhea, abdominal
discomfort, dizziness, photophobia, irritability, headache, and
heartburn; however, regardless of the dosage used, few untoward
effects have been previously reported. In our study, no serious
adverse effects were recorded in any of the 80 randomly assigned
subjects. Overall, only 3 patients (3.8%) of the placebo group re-
ported an adverse event, usually moderate and considered unre-
lated to the study drug. These were abdominal pain and discomfort
(n ¼ 2), and orthostatic intolerance (n ¼ 1). However, these three
patients were excluded from the study in order to avoid the in-
ﬂuence of these symptoms on the evaluated variables. There were
no statistical differences in the number of adverse events between
groups (P¼ 0.110). The studywas conducted in accordancewith the
guidelines laid down in the Declaration of Helsinki. The study
Fig. 1. Flowchart of the study participants. Consolidated Standards of Reporting Trials (CONSORT) ﬂow diagram showing the distribution of the participants from initial assessment
to analysis of study data. CFS, Chronic Fatigue Syndrome; CoQ10, Coenzyme Q10; NADH, reduced nicotinamide adenine dinucleotide.
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Ethics Committee of the Vall d'Hebron University Hospital, Barce-
lona, Spain. Informed written consent was obtained from each of
the study participants.
2.3. Study design
A proof-of-concept, 8-week, randomized, double-blind, pla-
cebo-controlled trial was conducted at a single tertiary referral
center in order to evaluate the effects of oral CoQ10 plus NADH
supplementation on max HR changes during an incremental exer-
cise test using a cycle ergometer with continuous monitoring of
cardiovascular response and on CFS related symptoms (fatigue,
pain and sleep disturbances) in 80 eligible Spanish CFS patients
who fulﬁlled the 1994 CDC case criteria. The patients were evalu-
ated at baseline and at the end of the run-in period (8-weeks)
regarding age-predicted max HR functional response with an in-
cremental cycle ergometer test. Changes in fatigue, pain and sleep
problems were assessed through patient self-reported question-
naires from baseline to each follow-up visits (at 4- and 8-weeks).
2.4. Primary outcome measure
The protocol-deﬁned outcomemeasurewas to evaluate themax
HR changes as measured by an exercise test on a cycle ergometer
from baseline to the end of treatment period (8-weeks). The sub-
jects performed a cycle ergometer test against a graded increase in
workload, until exhaustion was reached. The exercise tests were
performed at a humidity of 40%e 60% and at room temperature
(20 Ce22 C). The subjects were asked to adopt a sitting position
on the electromagnetically braked ergometer (Angio, Lode B.V.,
Groningen, The Netherlands) and, after three to ﬁve minutes of
adjustment to the position, the test was started. Heart rate was
monitored continuously at rest and during exercise. Twelve-leadelectrocardiogram and HR were monitored continuously during
the test (Cardio Scan v.4.0, DM software, Stateline, Nevada, USA),
obtaining HR at each stage of the test. VO2 peak (L/min) and relative
VO2 peak (ml/kg/min) were measured breath-by-breath with an
automatic gas analysis system (Metasys TR-plus, Brainware SA, La
Valette-du-Var, France) equipped with a pneumotachometer and
making use of a two-way mask (Hans Rudolph, Shawnee, Kansas,
USA). Gas and volume calibrations were performed before each
test, in accordance with the manufacturer's guidelines. After a four-
minute period cycling at 0 W, participants followed a 20 W/min
ramp protocol up to exhaustion, which was the maximal test. In a
previous study, the exercise capacity stress testing protocol was
able to distinguish women with CFS from healthy sedentary con-
trols [21]. The following physiological variables were obtained
during the exercise test: pulmonary oxygen uptake (VO2), pulmo-
nary carbon dioxide output (VCO2), maximal workload, heart rate
(HR), respiratory quotient, arm blood pressure (BP) and perceived
exertion based on the B€org scale (scores 6 to 20).2.5. Secondary outcome measures
Secondary outcome measures included changes in fatigue, pain
and sleep problems assessed through validated self-reported
questionnaires from baseline to each follow-up visits (4 and 8
weeks). The above symptoms were recorded through patient self-
reported assessment scales by trained investigators who super-
vised compliance. Fatigue was scored using the Fatigue Impact
Scale (FIS) [22], a 40-item questionnaire which assesses percep-
tions of how fatigue affects cognitive, physical and psychosocial
functions. This validated, self-administered questionnaire has been
used in a number of fatigue-associated diseases, including CFS.
Participants rate how these items are affected by fatigue on a ﬁve-
point scale: 0 (no fatigue) to 4 (severe fatigue). The total score is
calculated by adding responses from the 40 questions (range
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fatigue. Painwas scored using the McGill Pain Questionnaire (MPQ)
[23], a validated instrument composed of 15 numerically scaled
questions rated from 0 (no pain) to 3 (severe pain). These items
measure two dimensions of subjective pain: sensory (11 items) and
affective (4 items). Finally, sleep disruptionwere assessed using the
24-item Pittsburgh Sleep Quality Index (PSQI) questionnaire [24].
Scores are obtained on each of seven components of sleep quality:
subjective quality, sleep latency, sleep duration, habitual sleep ef-
ﬁciency, sleep perturbations, use of hypnotic medication, and
daytime dysfunction. Each component is scored from 0 to 3 (0 ¼ no
problems and 3 ¼ severe problems). Global PSQI score ranges from
0 to 21, with higher scores indicating more sleep problems.
2.6. Sample size and statistical analysis
Efﬁcacy data were analyzed on the basis of an intention-to-treat
population approach, which included patients who had been
treated for at least 30 consecutive days. Missing values were
imputed by the last observation carried forward method. All pa-
tients who were randomized were considered for safety analysis. A
descriptive analysis for demographic and clinical data was per-
formed on the number of valid cases by means of absolute and
relative frequencies, measures of central tendency (mean and
median) and dispersion (standard deviations (SD), minimum and
maximum). The sample was checked for normal distribution and
homogeneity of the variance using the KolmogoroveSmirnov test
and the Levene test, respectively. Since all data were normally
distributed, one-factor ANOVA test was used to compare the mean
values of variables. A chi-square test (c2) or Fisher's exact test were
used to assess differences in categorical variables. According to the
pre-speciﬁed primary analysis plan, treatment effect was assessed
as the mean change in the max HR from baseline to 8-weeks (max
HR at week 8 minus max HR baseline visit) for each intervention
group. Statistical comparison between treatment effects onmax HR
changes was made by analysis of covariance (ANCOVA) in a model
that adjusted for the change in thework-load between baseline and
ﬁnal exercise test. Treatment effect on the secondary outcome
measures was calculated (week 4 score minus baseline score, and
week 8 scoreminus baseline score) and differences between groups
were evaluated by ANCOVA adjusted by the basal score of the
parameter analyzed. Regarding the ﬁnal sample size, the study
detected differences of 5 points in the max HR with a power of 75%Table 1
Baseline demographic, clinical and laboratory characteristics among 73 chronic fatigu
Variable CoQ10 þ NADH grou
(n ¼ 39)
Age, y 49.3 ± 7.1
Duration of fatigue, y 15.4 ± 8.9
Time of symptoms onset, y 33.9 ± 6.8
Body weight, kg 68.5 ± 14.6
Height, m 1.7 ± 0.07
BMI, kg/m2 23.7 ± 5.2
Type 2 diabetes 5 (13)
Fibromyalgia 17 (44)
Irritable bowel syndrome 3 (8)
Hypothyroidism 6 (15)
Analgesic/anti-inﬂammatory drugs 12 (31)
Antidepressants/anxiolytics 19 (49)
Hypnotics 6 (15)
CoQ10, pmole/mg protein 135.8 ± 22
NADH, pmole/106 PBMC 95.3 ± 2.1
Data are expressed as mean ± standard deviation for continuous variables, and categ
a Obtained by using an one-factor ANOVA test for continuous variables.
b Obtained by using a chi-square test (c2) or Fisher's exact test for categorical variaat an alpha-level of 0.05. For all analyses, a P-value < 0.05 was
considered statistically signiﬁcant. All statistical analyses were
performed using SPSS, version 18.0 for Windows (IBM Corp.,
Armonk, NY, USA).
3. Results
3.1. Study participants
An 8-week randomized, placebo-controlled, double-blind trial
was conducted at a single tertiary center (CFS Clinical Unit, Vall
d'Hebron University Hospital, Barcelona, Spain) from January to
December 2013. Figure 1 shows a ﬂowchart of the participants prior
to analysis. Dropout was deﬁned as missing data on lost to follow-
up visits from baseline. One patient in the CoQ10 plus NADH group
was lost to follow-up and excluded from the study. In the placebo
group, six patients were also excluded, for the following reasons:
refusal to participate (n¼ 2), loss of a cycling ergometer test (n¼ 1)
and adverse effects (n ¼ 3). Therefore, 73 participants
[CoQ10þNADH (n¼ 39) andmatching placebo (n¼ 34)] completed
the trial. However, the statistical analyses were performed on the
original 80 participants on the basis of an intention-to-treat
approach, and missing values for these seven excluded subjects
were determined on the basis of the last observation carried for-
ward method. The rate of compliance in the study was high, since
100% of tablets were taken throughout the study in both groups.
Additionally, analyses of CoQ10 and NADH levels in PBMC at week 8
showed clear differences between the groups [CoQ10: treatment
group: 361.8 ± 37 vs. placebo: 155.1 ± 26spmole/mg proteins;
P < 0.05 and NADH: treatment group: 247.3 ± 5.1 vs. placebo:
98.2± 4.6 pmole/106 PBMC; P < 0.001]. Means (±SD) weight, height
and BMI of all participants were 70.3 ± 13.3 kg (range 42e106),
1.8 ± 0.1 m (range 1.6e1.9) and 23 ± 4.9 kg/m2 (range 17e43),
respectively. Baseline data on demographic and clinical character-
istics, associated comorbid conditions, pharmacological therapy
used and baseline CoQ10 and NADH levels did not differ signiﬁ-
cantly between the groups (Table 1).
3.2. Primary outcome measure
Table 2 summarizes the results of main functional physiological
variables, before and after an incremental cycle ergometer test at
baseline and week 8 of intervention between both randomizatione syndrome patients according to treatment assigned at enrollment.
p Placebo
(n ¼ 34)
P valuea,b
49.1 ± 8.4 0.96
14.7 ± 6.2 0.86
34.4 ± 2.5 0.68
72.1 ± 13.7 0.79
1.8 ± 0.02 0.53
22.3 ± 2.4 0.93
4 (12) 0.95
13 (38) 0.91
2 (6) 0.57
4 (12) 0.75
8 (24) 0.73
11 (32) 0.41
4 (12) 0.81
137.2 ± 13 0.53
96.7 ± 2.4 0.71
orical variables as number (percentage) for group.
bles.
Table 2
Rest and maximum functional physiological data during the incremental cycle ergometer stress test at baseline and week 8 of intervention between randomization arms.
Physical Week 0 Week 8
Performance variables Rest Maximum test Rest Maximum test
HR, bpm
CoQ10 þ NADH 81.7 ± 10.1 140.1 ± 15.3 79.0 ± 9.1 136.8 ± 14.2a
Placebo 82.6 ± 10.2 140.3 ± 19.8 80.7 ± 9.5 138.7 ± 17.4
Workload, km/h
CoQ10 þ NADH e 92.8 ± 20.7 e 93.2 ± 21.4
Placebo e 91.9 ± 21.7 e 88.8 ± 19.7
Respiratory quotient
CoQ10 þ NADH 0.81 ± 0.05 1.07 ± 0.11 0.83 ± 0.07 1.07 ± 0.1
Placebo 0.82 ± 0.05 1.06 ± 0.09 0.82 ± 0.05 1.08 ± 0.1
VO2, ml/kg/min
CoQ10 þ NADH 4.73 ± 0.92 19.4 ± 4.3 4.63 ± 0.95 18.6 ± 3.2
Placebo 4.91 ± 0.92 19.7 ± 3.3 4.74 ± 0.80 18.6 ± 3.8
VCO2, l/min
CoQ10 þ NADH 0.26 ± 0.05 1.4 ± 0.3 0.25 ± 0.05 1.3 ± 0.3
Placebo 0.27 ± 0.06 1.4 ± 0.3 0.26 ± 0.05 1.4 ± 0.4
Systolic BP, mm Hg
CoQ10 þ NADH 119.9 ± 15.6 139.8 ± 19.5 118.1 ± 15.6 136.4 ± 19.3
Placebo 115.9 ± 15.9 135.6 ± 22.2 113.4 ± 13.7 132.9 ± 20.2
Diastolic BP, mm Hg
CoQ10 þ NADH 70.1 ± 10.7 72.6 ± 14.1 68.4 ± 11.1 70.2 ± 14.1
Placebo 70.2 ± 11.9 69.7 ± 13.4 67.6 ± 8.17 69.3 ± 10.5
Data are expressed as mean ± standard deviation.
a An one-factor ANOVA test was used comparing intragroup maximum HR scores vs. baseline. Statistical signiﬁcance at *P < 0.05.
Fig. 2. The changes in participants treated with CoQ10 þ NADH or placebo were
determined on the basis of the changes in max HR during the cycle ergometer test
from baseline to week 8. More negative scores indicate more diminishment of the max
HR value from baseline.
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change) statistically signiﬁcant differences were observed in
CoQ10 þ NADH group during the study, with a reduction in max HR
after 8 weeks of treatment compared with baseline max HR
(136.8 ± 14.2 vs. 140.1 ± 15.3 bpm, P ¼ 0.022). Comparing max HR
change at the end of the exercise test from baseline to week 8 be-
tween groups, the treatment did not have a signiﬁcant effect on
max HR in study participants. However, as shown in Fig. 2, there
was a clear trend towards a greater max HR reduction to week 8 in
the treatment group (CoQ10þ NADH group:3.28 ± 8.7 vs. placebo
group: 1.82 ± 12.2, F ¼ 3.53; P-trend ¼ 0.225). There were no
differences in the change in VO2, VCO2, maximal workload, respi-
ratory quotient and arm systolic and diastolic blood pressure from
baseline to week 8 (P > 0.05). The perceived effort during the ex-
ercise, assessed by the change of the B€org test score from baseline
to week 8, did not differ between both intervention groups
(CoQ10 þ NADH group: 0.25 ± 1.35 vs. placebo group: 0.12 ± 1.63,
F ¼ 0.15; P ¼ 0.66).
3.3. Secondary outcome measures
Table 3 shows the fatigue and pain scores at baseline, weeks 4
and 8 and the changes between the intervention groups. Patients
treated with CoQ10 þ NADH presented signiﬁcant reductions in FIS
total scores from baseline to 4- and 8-weeks of treatment
(P ¼ 0.021 and P ¼ 0.03, respectively). There were also signiﬁcant
differences in mean FIS total score in the placebo group, but only at
4 weeks of treatment compared to baseline (P ¼ 0.04). As shown in
Fig. 3, there was a more marked trend towards decrease of the
mean FIS total scores and physical, cognitive and psychosocial FIS
subscores in the CoQ10þ NADH group between baseline and weeks
4 and 8. However, as shown in Table 3, the changes in FIS total score
and in physical, cognitive and psychosocial FIS subscores did not
differ between the groups from baseline to weeks 4 and 8. On the
other hand, a signiﬁcant decrease in sensory and affective pain
perception was observed in the placebo group from baseline to
week 8 (21.8 ± 6.0 vs. 17.7 ± 7.4, P ¼ 0.01 and 8.9 ± 3.1 vs. 6.8 ± 3.6,
P ¼ 0.01, respectively). The changes in sensory and affective pain
perception (treatment effect) from baseline to week 8 were higherin placebo group compared to active group (- 4.35 ± 7.5 vs.
1.59 ± 6.4, P ¼ 0.002 and e 1.94 ± 3.8 vs. 0.41 ± 3.7, P ¼ 0.006,
respectively). Finally, Table 4 shows the data for quality of sleep
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in the two groups. Patients with CoQ10 þ NADH had fewer sleep
disturbances at week 8 (F ¼ 3.83, P < 0.001) and were taking more
hypnotic drugs (F ¼ 2.75, P ¼ 0.008).
4. Discussion
New therapeutic strategies for CFS are urgently needed since its
symptoms cause substantial impairments in patients' quality of life
and currently there is no FDA-approved effective treatment. To our
knowledge, this is the ﬁrst randomized, placebo-controlled, dou-
ble-blind clinical trial to evaluate the potential beneﬁcial effects of
oral CoQ10 plus NADH supplementation on maximum HR changes
in CFS patients performing an incremental cycle ergometer stress
test, and also their perceptions of fatigue, pain and sleep distur-
bances in CFS patients. Our results suggest that CoQ10 plus NADH
supplementation may have a positive effect on max HR change
during the maximal cycle ergometer test and patients' perception
of fatigue. Although the differences in the effect of treatment be-
tween the two groups were not statistically signiﬁcant, this may
have been due to not enough study power; in view of the positive
trend found for the combination of CoQ10 plus NADH, we consider
that this study should be continued with a larger number of pa-
tients in CFS subgroups more homogeneous. CFS patients presentTable 3
Fatigue and pain scores at baseline, week 4 and 8 and changes from baseline after of in
FIS and MPQ CoQ10 þ NADH (n ¼ 39)
Fatigue Index Scale-40
FIS total scorea
Basal 131.9 ± 18.9
Week 4 125.4 ± 22.4
Week 8 124.4 ± 23.4
Treatment effect (week 4)b 6.51 ± 17.1
Treatment effect (week 8) 7.46 ± 18.6
Physical
Basal 34.8 ± 4.2
Week 4 32.3 ± 5.8
Week 8 32.4 ± 5.9
Treatment effect (week 4) 2.44 ± 4.9
Treatment effect (week 8) 2.41 ± 5.2
Cognitive
Basal 33.6 ± 5.1
Week 4 31.9 ± 6.1
Week 8 31.4 ± 6.0
Treatment effect (week 4) 1.69 ± 4.7
Treatment effect (week 8) 2.15 ± 5.1
Psychosocial
Basal 63.5 ± 10.9
Week 4 61.2 ± 11.9
Week 8 60.6 ± 12.6
Treatment effect (week 4) 2.4 ± 9.3
Treatment effect (week 8) 2.9 ± 10.2
McGill Pain Questionnaire [2]
Sensory
Basal 20.2 ± 4.7
Week-4 19.9 ± 6.6
Week-8 21.8 ± 6.0
Treatment effect (week 4) 2.6 ± 6.1
Treatment effect (week 8) 1.59 ± 6.4
Affective
Basal 8.5 ± 2.6
Week 4 8.3 ± 3.0
Week 8 8.9 ± 3.1
Treatment effect (week 4) 0.21 ± 3.4
Treatment effect (week 8) 0.41 ± 3.7
Data are expressed as mean ± standard deviation.
a On the FIS and MPQ, higher scores indicate greater severity of fatigue or pain perc
b Treatment effect was calculated as changes from baseline to week 4 and 8 (last obse
from the analysis of covariance. Negative numbers in treatment effect scores indicate
c An ANCOVA test was used for the intergroup statistical analysis.multiple symptoms, including physical and mental fatigue, pain
and sleep disruption. Some studies have suggested that they show
normal resting HR but blunted HR and systolic BP responses during
exercise [25,26]. However, other studies have not reported HR re-
ductions, and attribute some of the observed effects to reduced
effort [27]. The discrepancies between different studies and treat-
ment outcomesmay be due to the heterogeneity of CFS populations
(patients' heterogeneous clinical characteristics, study entry case
criteria, the role of intervention provider, centre-speciﬁc charac-
teristics, co-therapies, comorbidities, study designs, and outcome
variability is a critical aspect to consider) and that sample sizes
were small. Lack of consistency of outcome measures in interven-
tion trials for CFS might be a function of combining patients into a
large heterogeneous group rather than analyzing them within
subgroups. The etiology of CFS remains unclear. Several biochem-
ical and immune abnormalities in inﬂammatory, oxidative and
nitrosative stress (O&NS) pathways [28], and recent studies have
suggested that mitochondrial disturbances to energy requirements
may be associated with the condition's pathogenesis [9]. The
reduction in mitochondrial function has been associated with a
decreased efﬁciency of oxidative phosphorylation and a fall in ATP
production. Two of these mitochondrial components are CoQ10 and
NADH. Dysfunctions in these two coenzymes have also been
associated with neurodegenerative diseases and cancer [29,30].tervention between treatment groups.
Placebo (n ¼ 34) P valuec
136.0 ± 16.0 0.32
127.5 ± 24.9 0.71
132.3 ± 20.7 0.14
8.56 ± 23.0 0.83
3.73 ± 17.5 0.27
35.6 ± 4.2 0.36
33.4 ± 6.4 0.48
34.2 ± 5.7 0.19
2.29 ± 6.4 0.73
1.47 ± 4.8 0.33
34.6 ± 4.3 0.35
32.4 ± 6.6 0.72
33.9 ± 4.9 0.06
2.21 ± 6.2 0.85
0.76 ± 5.0 0.11
65.7 ± 9.2 0.36
61.7 ± 12.9 0.86
64.2 ± 10.9 0.20
4.1 ± 11.6 0.67
1.5 ± 8.8 0.37
22.1 ± 5.6 0.20
19.9 ± 8.1 0.98
17.7 ± 7.4 0.01
2.2 ± 8.0 0.49
4.35 ± 7.5 0.002
8.8 ± 3.1 0.65
7.7 ± 3.6 0.42
6.8 ± 3.6 0.01
1.48 ± 3.4 0.28
1.94 ± 3.8 0.006
eption, respectively. FIS, fatigue index scale; MPQ, McGill pain questionnaire.
rvation minus baseline ones) and reported as adjusted (least squares) means ± SD
improvement from baseline.
J. Castro-Marrero et al. / Clinical Nutrition 35 (2016) 826e834832CoQ10 and NADH deﬁciencies have also been described in patients
with CFS and ﬁbromyalgia [9,12,31], and it has also been suggested
that serum NADH levels are directly correlated with serum CoQ10
concentration in these patients. Several components of the mito-
chondrial system require diet replacement and this need can be
facilitated with natural nutritional supplements [13]. Clinical trials
have shown the utility of using oral replacement supplements of
CoQ10 and/or NADH to signiﬁcantly reduce the fatigue levels and
other symptoms associated with chronic diseases, neuropsychiatric
conditions and ﬁbromyalgia [18,32]. However, studies carried out in
CFS have included only very small samples and their conclusions
are inconsistent [14e16]. Additionally, although combinations of
different oral dietary supplements have been proposed, to date no
clinical trials with the association of CoQ10 plus NADH in CFS have
been published [13]. Therefore, we evaluated the combination of
CoQ10 with NADH in a nutraceutical formulation because it may
have a synergistic antioxidant effect. Some studies have suggested
that CoQ10 or NADH may have a positive effect on max HR change
and physical exercise in CFS. A previous study by our group sug-
gested that oral NADH was associated with decreases in max HR
after a stress test in a CFS population [14]. Our results partially
concur with these previous reports and suggest that the combi-
nation of CoQ10 and NADH may improve max HR during an incre-
mental cycle ergometer stress test. At present, few studies have
been published that analyze the mechanisms by which CoQ10 and
NADH inﬂuence cardiovascular response [15,16,19,20]. It has been
suggested that these molecules may modulate the autonomic
function by regulating the synthesis of endogenous catecholamines
and acetylcholine [10]. It has also been proposed that they can
improve the endothelial function and as a consequence increaseFig. 3. Changes in FIS scoring during each follow-up visits. Each point on the curve indicate
signiﬁcant differences in all the FIS scores were observed between both intervention groupleft ventricular contractility and cardiac function [18]. However,
future research are warranted to further clarify the exact mecha-
nisms by which CoQ10 and NADH inﬂuence cardiovascular function
in the general population and in CFS patients. Little information is
available on the effect of CoQ10 or NADH in fatigue and other CFS
associated symptoms. Some studies conclude that NADH had a
positive effect on fatigue perception in some patients, although one
of them suggested that the effect was limited to the ﬁrst trimester
of the treatment [16]. To our knowledge, no studies published to
date have analyzed the efﬁcacy and tolerance of CoQ10 plus NADH
administration on fatigue levels, pain perception and sleep prob-
lems in CFS. In view of our observation of a trend towards a
reduction in the perception of fatigue in the group treated with this
combination compared to placebo, further studies with larger
samples of CFS patients are warranted in order to conﬁrm our
ﬁndings. The lack of any effect on pain was an unexpected result.
Although pain response in CFS patients has not been previously
analyzed, a possible effect of CoQ10 or NADH on pain perception has
been suggested in other pathologies such as ﬁbromyalgia [31]. In
view of the study's design, any description of the mechanisms
underlying the results would be purely speculative and would need
to be conﬁrmed in future studies. It is known that pain is a symp-
tom that can be decreased by the placebo effect. We therefore
believe that the group receiving non-active treatment was more
sensitive to the placebo effect than the active group, since they
were anticipating a certain improvement. Patients receiving active
treatment would detect the objective improvement in certain
symptoms (mainly fatigue) deriving from CoQ10 and NADH and
would therefore be less sensitive to the less intense placebo
response. For the effect on sleep, the results reported so far are alsos mean FIS scoring. Lower scores means an improvement in the fatigue perception. No
s in each study visits.
Table 4
Sleep scores at baseline, week 4 and 8 and change from baseline after intervention in
participants who received either CoQ10 þ NADH or placebo [1].
PSQIa CoQ10 þ NADH
(n ¼ 39)
Placebo
(n ¼ 34)
P valuec
Subjective sleep quality
Basal 2.3 ± 0.7 2.4 ± 0.6 0.30
Week 4 2.3 ± 0.8 2.1 ± 1.0 0.36
Week 8 2.5 ± 0.8 2.4 ± 0.7 0.77
Treatment effect (week 4)b 0.03 ± 09 0.32 ± 1.01 [3] 0.12
Treatment effect (week 8) 0.18 ± 0.9 0.03 ± 0.8 0.62
Sleep latency
Basal 2.1 ± 0.7 2.5 ± 0.7 0.04
Week 4 1.95 ± 0.9 2.4 ± 0.8 0.04
Week 8 2.1 ± 0.8 2.4 ± 0.7 0.09
Treatment effect (week 4) 0.18 ± 0.8 0.09 ± 0.8 0.63
Treatment effect (week 8) 0.08 ± 0.8 0.12 ± 0.7 0.43
Sleep duration
Basal 1.9 ± 1.0 1.9 ± 0.8 0.93
Week 4 1.8 ± 1.1 1.9 ± 1.0 0.64
Week 8 2.3 ± 1.1 1.9 ± 0.9 0.13
Treatment effect (week 4) 0.15 ± 0.8 0.06 ± 0.6 0.57
Treatment effect (week 8) 0.33 ± 1.3 0.03 ± 0.8 0.12
Habitual sleep efﬁciency
Basal 1.8 ± 1.3 2.0 ± 1.3 0.49
Week 4 1.8 ± 1.4 2.0 ± 1.3 0.51
Week 8 2.2 ± 1.2 2.1 ± 1.3 0.56
Treatment effect (week 4) 0.03 ± 1.3 0.03 ± 1.1 0.99
Treatment effect (week 8) 0.41 ± 1.4 0.03 ± 1.5 0.38
Sleep disturbances
Basal 2.2 ± 0.5 2.3 ± 0.6 0.29
Week 4 2.0 ± 0.6 2.2 ± 0.6 0.07
Week 8 2.0 ± 0.5 2.5 ± 0.5 <0.001
Treatment effect (week 4) 0.18 ± 0.7 0.06 ± 0.60 0.44
Treatment effect (week 8) 0.13 ± 0.6 0.18 ± 0.8 0.001
Hypnotic medication use
Basal 1.8 ± 1.4 2.2 ± 1.3 0.22
Week 4 2.0 ± 1.4 1.7 ± 1.3 0.35
Week 8 2.2 ± 1.3 1.3 ± 1.4 0.008
Treatment effect (week 4) 0.10 ± 1.5 0.6 ± 1.7 0.070
Treatment effect (week 8) 0.31 ± 1.5 0.94 ± 1.8 0.002
Daytime disfunction
Basal 2.5 ± 0.7 2.5 ± 0.7 0.82
Week 4 2.5 ± 0.8 2.3 ± 0.9 0.38
Week 8 2.6 ± 0.7 2.4 ± 0.7 0.24
Treatment effect (week 4) 0.01 ± 0.8 0.21 ± 0.9 0.31
Treatment effect (week 8) 0.15 ± 0.9 0.09 ± 0.8 0.18
Global Psqi score
Basal 14.6 ± 3.4 15.9 ± 3.2 0.10
Week 4 14.2 ± 4.4 14.6 ± 4.4 0.73
Week 8 15.8 ± 4.5 14.9 ± 2.7 0.31
Treatment effect (week 4) 0.41 ± 3.7 1.35 ± 3.2 0.25
Treatment effect (week 8) 0.03 ± 0.8 0.03 ± 0.8 0.05
Data are expressed as mean ± standard deviation.
a On the PSQI, higher scoring indicates more sleep disturbances. PSQI, Pittsburgh
Sleep Quality Index.
b Treatment effect was calculated as changes from baseline to week 4 and 8 (last
observation less baseline ones), and reported as adjusted (least squares) means ± SD
from the analysis of covariance. Negative values on the treatment effect scores
indicate improvement from baseline.
c An ANCOVA test was used for the intergroup statistical analysis.
J. Castro-Marrero et al. / Clinical Nutrition 35 (2016) 826e834 833inconsistent. A recent clinical trial in a sample of Gulf War veterans
concluded that CoQ10 (100 mg/day) conferred beneﬁts to physical
function and symptoms, but not sleep [32]. Though the differences
in the samples should not be overlooked, the ﬁndings of that study
are in agreement with ours. In our sample, some of the patients also
had ﬁbromyalgia and other comorbid conditions frequently asso-
ciatedwith CFS. Although therewere no differences in these clinical
parameters between the two groups, future studies should evaluate
the effect of these treatments in more homogeneous subgroups of
CFS populations as noted above. Previous reports have suggested
that dietary supplements such as CoQ10 or NADH are safe and welltolerated [12,14]. Our results conﬁrm these observations and sug-
gest that moderate doses of these molecules can be generally safety
and well tolerated added to conventional therapy in CFS. This study
has some limitations that should be noted. First, because of the
small sample size, the study may have lacked the power to detect
statistically signiﬁcant differences in max HR changes between
treatments. However, it was designed as a proof-of-concept trial
and we consider that our research can serve as a basis for further
studies enrolling larger numbers of participants in order to conﬁrm
these ﬁndings. The second limitation derives from the origin of the
sample. The fact that all patients were recruited from a single ter-
tiary referral center may have increased the proportion of more
severe patients and we should be cautious in generalizing the re-
sults to patients seen in other medical settings or to the general
population. Third, doses and timing were pre-established, and so
the dose-response effect cannot be analyzed. It may be useful to
consider higher dosages and longer interventions to determine
their potential beneﬁt. Finally, it has been stated that ergometric
response is inﬂuenced by gender; therefore, our results may be
conditioned by the lack of men in the sample. However, since CFS is
more prevalent in women we preferred to study a more homoge-
neous and representative sample [21]. Nevertheless, our study had
important strengths: 1) few previous studies have analyzed the
combination of CoQ10 with NADH as nutritional supplement in CFS;
2) the use of a incremental cycle ergometer stress test protocol as
an objective measure to evaluate the effect of dietary supplements
on max HR change has not been previously analyzed, and very little
information is available regarding its effect on fatigue levels, pain
perception and sleep disruption; 3) the use of strict inclusion
criteria based on 1994 CDC case deﬁnition ensures that the par-
ticipants were appropriately selected and without confounding
comorbidities. In conclusion, this 8-week, randomized, double-
blind, placebo-controlled trial suggested that the CoQ10 plus
NADH supplementation may be a safe, well tolerated and poten-
tially useful treatment. Beside, CoQ10 plus NADH supplementation
improved signiﬁcantly reducing max HR during the ergometer
stress test and also on perceived fatigue in CFS. On the contrary,
CoQ10 plus NADH supplementation had no positive effect on pain
and sleep disturbances between the intervention groups. Larger
multicenter trials with longer term follow-up interventions inmore
homogenous CFS populations are warranted to assess these ﬁnd-
ings and to produce evidence-based guidelines regarding the po-
tential beneﬁts of antioxidant therapy in CFS and other chronic
conditions.
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